Trial Profile
A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Fluticasone propionate (Primary) ; Salmeterol (Primary) ; Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms WISDOM
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 19 May 2021 Results of pooled analysis from six studies (TONADO 1-2, DYNAGITO, WISDOM, UPLIFT and TIOSPIR) comparing the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderate-to-severe COPD and a predominantly lower exacerbation risk, presented at the 117th International Conference of the American Thoracic Society.
- 18 May 2016 Results (post hoc analysis, n = 262) assessing lung-function profile before and after the first moderate to severe exacerbation presented at the 112th International Conference of the American Thoracic Society.
- 18 May 2016 Results of a post hoc subgroup analysis (n=2296) presented at the 112th International Conference of the American Thoracic Society